Identification

Name
Chlorpropamide
Accession Number
DB00672  (APRD00029)
Type
Small Molecule
Groups
Approved, Investigational
Description

Chlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Chlorpropamide is not recommended for the treatment of NIDDM as it increases blood pressure and the risk of retinopathy (UKPDS-33). Up to 80% of the single oral dose of chlorpropramide is metabolized, likely in the liver; 80-90% of the dose is excreted in urine as unchanged drug and metabolites. Renal and hepatic dysfunction may increase the risk of hypoglycemia.

Structure
Thumb
Synonyms
  • 1-(P-Chlorobenzenesulfonyl)-3-propylurea
  • 1-(P-Chlorophenylsulfonyl)-3-propylurea
  • 1-Propyl-3-(P-chlorobenzenesulfonyl)urea
  • 4-chloro-N-((Propylamino)carbonyl)benzenesulfonamide
  • 4-chloro-N-[(Propylamino)carbonyl]benzenesulfonamide
  • Chlorpropamid
  • Chlorpropamide
  • Chlorpropamidum
  • Clorpropamida
  • N-(4-Chlorophenylsulfonyl)-n'-propylurea
  • N-(P-Chlorobenzenesulfonyl)-n'-propylurea
  • N-Propyl-n'-(P-chlorobenzenesulfonyl)urea
  • N-Propyl-n'-P-chlorophenylsulfonylcarbamide
External IDs
Hoechst 18810 / P 607 / U 9818
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Chlorpropamide Tab 100mgTablet100 mgOralApotex Corporation1977-12-31Not applicableCanada
Apo Chlorpropamide Tab 250mgTablet250 mgOralApotex Corporation1974-12-31Not applicableCanada
Chlorpropamide 100 Tab USPTablet100 mgOralPro Doc Limitee1983-12-312009-07-23Canada
Chlorpropamide Tab 250mgTablet250 mgOralDuchesnay Inc.1978-12-312003-07-18Canada
Chlorpropamide Tab 250mgTablet250 mgOralPro Doc Limitee1969-12-312009-07-23Canada
Diabinese Tab 100mgTablet100 mgOralPfizer1958-12-312000-10-18Canada
Diabinese Tab 250mgTablet250 mgOralPfizer1958-12-312000-07-26Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ChlorpropamideTablet100 mg/1OralMylan Pharmaceuticals1984-06-01Not applicableUs
ChlorpropamideTablet250 mg/1OralPd Rx Pharmaceuticals, Inc.1984-06-01Not applicableUs
ChlorpropamideTablet250 mg/1OralMylan Pharmaceuticals1984-06-01Not applicableUs
Novo-propamide 250mgTablet250 mgOralNovopharm Limited1969-12-312010-09-10Canada
International/Other Brands
Abemide (Kobayashi Kako) / Chloronase (Hoechst) / Dabinese (Pfizer) / Diabeedol (Sriprasit Dispensary) / Diabemide (Guidotti) / Diabezin (Prince) / Diabinese (Pfizer) / Diabitex (Plantex-Ikapharm) / Dibecon (Pharmasant) / Glycemin (Siam Bheasach) / Hypomide (Aspen Pharmacare) / Litangen (Ming Ta) / Propamide (Atlantic) / Trane (Omega)
Categories
UNII
WTM2C3IL2X
CAS number
94-20-2
Weight
Average: 276.74
Monoisotopic: 276.033540689
Chemical Formula
C10H13ClN2O3S
InChI Key
RKWGIWYCVPQPMF-UHFFFAOYSA-N
InChI
InChI=1S/C10H13ClN2O3S/c1-2-7-12-10(14)13-17(15,16)9-5-3-8(11)4-6-9/h3-6H,2,7H2,1H3,(H2,12,13,14)
IUPAC Name
1-(4-chlorobenzenesulfonyl)-3-propylurea
SMILES
CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1

Pharmacology

Indication

For treatment of NIDDM in conjunction with diet and exercise.

Associated Conditions
Pharmacodynamics

Chlorpropamide, a second-generation sulfonylurea antidiabetic agent, is used with diet to lower blood glucose levels in patients with diabetes mellitus type II. Chlorpropamide is twice as potent as the related second-generation agent glipizide.

Mechanism of action

Sulfonylureas such as chlorpropamide bind to ATP-sensitive potassium channels on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.

TargetActionsOrganism
AATP-binding cassette sub-family C member 8
inhibitor
Human
Absorption

Readily absorbed from the GI tract. Peak plasma concentrations occur within 2-4 hours and the onset of action occurs within one hour. The maximal effect of chlorpropamide is seen 3-6 hours following oral administration.

Volume of distribution
Not Available
Protein binding

Highly bound to plasma proteins.

Metabolism

Up to 80% of dose is metabolized likely through the liver to to 2-hydroxylchlorpropamide (2-OH CPA), p-chlorobenzenesulfonylurea (CBSU), 3-hydroxylchlorpropamide (3-OH CPA), and p-chlorobenzenesulfonamide (CBSA); CBSA may be produced by decomposition in urine. It is unknown whether chlorpropamide metabolites exert hypoglycemic effects.

Route of elimination

80-90% of a single oral dose is excreted in the urine as unchaged drug and metabolites within 96 hours.

Half life

Approximately 36 hours with interindividual variation ranging from 25-60 hours. Duration of effect persists for at least 24 hours.

Clearance
Not Available
Toxicity

IPN-RAT LD50 580 mg/kg

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Glucose-6-phosphate 1-dehydrogenaseVilleurbanneNot Available1000_1002delACCADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTorunNot Available1006A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSunderlandNot Available105_107delCATADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseIwatsukiNot Available1081G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSerresNot Available1082C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTondelaNot Available1084_1101delCTGAACGAGCGCAAGGCCADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLoma LindaNot Available1089C->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAachenNot Available1089C->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTenriNot Available1096A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMontpellierNot Available1132G>AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCalvo MackennaNot Available1138A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseRileyNot Available1139T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseOlomoucNot Available1141T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTomahNot Available1153T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLynwoodNot Available1154G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMadridNot Available1155C->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseIowa, Walter Reed, SpringfieldNot Available1156A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBeverly Hills, Genova, Iwate, Niigata, YamaguchiNot Available1160G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHartfordNot Available1162A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePrahaNot Available1166A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKrakowNot Available1175T>CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseWisconsinNot Available1177C->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNashville, Anaheim, PorticiNot Available1178G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAlhambraNot Available1180G->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBariNot Available1187C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePuerto LimonNot Available1192G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCovao do LoboNot Available1205C>AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseClinicNot Available1215G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseUtrechtNot Available1225C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSuwalkiNot Available1226C->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseRiversideNot Available1228G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseJapan, ShinagawaNot Available1229G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKawasakiNot Available1229G->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMunichNot Available1231A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseGeorgiaNot Available1284C->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSumareNot Available1292T->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTelti/KobeNot Available1318C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSantiago de Cuba, MoriokaNot Available1339G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHarimaNot Available1358T->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseFiguera da FozNot Available1366G->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAmiensNot Available1367A>TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBangkok NoiNot Available1376G->T, 1502T->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseFukayaNot Available1462G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCampinasNot Available1463G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBuenos AiresNot Available1465C>TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseArakawaNot Available1466C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBrightonNot Available1488_1490delGAAADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKozukataNot Available159G->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAmsterdamNot Available180_182delTCTADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNo nameNot Available202G->A, 376A->G, 1264C>GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSwanseaNot Available224T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseUrayasuNot Available281_283delAGAADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseVancouverNot Available317C->G544C->T592C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMt SinaiNot Available376A->G, 1159C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePlymouthNot Available488G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseVolendamNot Available514C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseShinshuNot Available527A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseChikugoNot Available535A->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTsukuiNot Available561_563delCTCADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePedoplis-CkaroNot Available573C>GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSantiagoNot Available593G->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMinnesota, Marion, Gastonia, LeJeuneNot Available637G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCincinnatiNot Available637G->T, 1037A->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHarilaouNot Available648T->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNorth DallasNot Available683_685delACAADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAsahikawaNot Available695G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseDurhamNot Available713A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseStonybrookNot Available724_729delGGCACTADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseWayneNot Available769C->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAveiroNot Available806G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCleveland CorumNot Available820G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLilleNot Available821A>TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBangkokNot Available825G>CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSugaoNot Available826C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLa JollaNot Available832T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseWexhamNot Available833C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePiotrkowNot Available851T>CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseWest VirginiaNot Available910G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseOmiyaNot Available921G->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNaraNot Available953_976delCCACCAAAGGGTACCTGGAC GACCADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseManhattanNot Available962G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseRehevotNot Available964T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHoniaraNot Available99A->G / 1360C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTokyo, FukushimaNot Available1246G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseChathamNot Available1003G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseFushanNot Available1004C->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePartenopeNot Available1052G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseIerapetraNot Available1057C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAnadiaNot Available1193A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAbenoNot Available1220A->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSurabayaNot Available1291G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePawneeNot Available1316G->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseS. AntiocoNot Available1342A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCassanoNot Available1347G->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHermoupolisNot Available1347G->C / 1360C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseUnion,Maewo, Chinese-2, KaloNot Available1360C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAndalusNot Available1361G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCosenzaNot Available1376G->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCanton, Taiwan- Hakka, Gifu-like, Agrigento-likeNot Available1376G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseFloresNot Available1387C->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKaiping, Anant, Dhon, Sapporo-like, WoseraNot Available1388G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKamogawaNot Available169C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCostanzoNot Available179T>CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAmazoniaNot Available185C->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSongklanagarindNot Available196T->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHechiNot Available202G->A / 871G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNamouruNot Available208T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBao LocNot Available352T>CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCrispimNot Available375G->T, 379G->T383T->C384C>TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAcrokorinthosNot Available376A->G / 463C->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSanta MariaNot Available376A->G / 542A->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAnanindeuaNot Available376A->G / 871G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseVanua LavaNot Available383T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseValladolidNot Available406C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBelemNot Available409C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLiuzhouNot Available442G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseShenzenNot Available473G>AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTaipei “Chinese- 3”Not Available493A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseToledoNot Available496C>TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNaoneNot Available497G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNankangNot Available517T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMiaoliNot Available519C->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMediterranean, Dallas, Panama‚ Sassari, Cagliari, BirminghamNot Available563C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCoimbra ShundeNot Available592C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNilgiriNot Available593G>AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseRadlowoNot Available679C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseRoubaixNot Available811G>CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHaikouNot Available835A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseChinese-1Not Available835A->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMizushimaNot Available848A>GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseOsakaNot Available853C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseViangchan, JammuNot Available871G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSeoulNot Available916G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLudhianaNot Available929G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseFarroupilhaNot Available977C->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseChinese-5Not Available1024C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseRignanoNot Available130G>AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseOrissaNot Available131C->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseG6PDNiceNot Available1380G>CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKamiube, KeelungNot Available1387C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNeapolisNot Available1400C->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAuresNot Available143T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSplitNot Available1442C->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKambosNot Available148C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePalestrinaNot Available170G>AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMetapontoNot Available172G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMusashinoNot Available185C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAsahiNot Available202G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseA- (202), Ferrara INot Available202G->A / 376A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMurcia OristanoNot Available209A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseUbe KonanNot Available241C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLagosantoNot Available242G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseGuangzhouNot Available274C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHammersmithNot Available323T->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSinnaiNot Available34G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseA- (680)Not Available376A->G / 680G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseA- (968), Betica,Selma, GuantanamoNot Available376A->G / 968T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSalerno PyrgosNot Available383T>GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseQuing YanNot Available392G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLagesNot Available40G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseIleshaNot Available466G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMahidolNot Available487G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMalagaNot Available542A->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSibariNot Available634A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMexico CityNot Available680G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNanningNot Available703C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSeattle, Lodi, Modena, Ferrara II, Athens-likeNot Available844G->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBajo MaumereNot Available844G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMontalbanoNot Available854G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKalyan-Kerala, Jamnaga, RohiniNot Available949G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseGaoheNot Available95A->GADR InferredIncreased risk of hemolytic anemia.Details

Interactions

Drug Interactions
DrugInteractionDrug group
(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE may increase the hypoglycemic activities of Chlorpropamide.Experimental
2,4-thiazolidinedione2,4-thiazolidinedione may increase the hypoglycemic activities of Chlorpropamide.Investigational
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Chlorpropamide.Experimental
AbirateroneThe metabolism of Chlorpropamide can be decreased when combined with Abiraterone.Approved
AcarboseAcarbose may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
AcebutololAcebutolol may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
AcenocoumarolChlorpropamide may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetohexamideAcetohexamide may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational, Withdrawn
Acetyl sulfisoxazoleThe metabolism of Chlorpropamide can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
Acetylsalicylic acidAcetylsalicylic acid may increase the hypoglycemic activities of Chlorpropamide.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Chlorpropamide.Approved
AICA ribonucleotideAICA ribonucleotide may increase the hypoglycemic activities of Chlorpropamide.Experimental, Investigational
AlaproclateAlaproclate may increase the hypoglycemic activities of Chlorpropamide.Experimental
AlbiglutideAlbiglutide may increase the hypoglycemic activities of Chlorpropamide.Approved
AllicinAllicin may increase the hypoglycemic activities of Chlorpropamide.Investigational
AllopurinolThe serum concentration of Chlorpropamide can be increased when it is combined with Allopurinol.Approved
AlogliptinAlogliptin may increase the hypoglycemic activities of Chlorpropamide.Approved
AloxiprinAloxiprin may increase the hypoglycemic activities of Chlorpropamide.Experimental
AlprenololAlprenolol may increase the hypoglycemic activities of Chlorpropamide.Approved, Withdrawn
Aluminium clofibrateAluminium clofibrate may increase the hypoglycemic activities of Chlorpropamide.Experimental
Aminosalicylic AcidAminosalicylic Acid may increase the hypoglycemic activities of Chlorpropamide.Approved
AmiodaroneThe metabolism of Chlorpropamide can be decreased when combined with Amiodarone.Approved, Investigational
Ammonium chlorideThe serum concentration of Chlorpropamide can be increased when it is combined with Ammonium chloride.Approved, Investigational, Vet Approved
AmphetamineAmphetamine may increase the hypoglycemic activities of Chlorpropamide.Approved, Illicit, Investigational
ApalutamideThe serum concentration of Chlorpropamide can be decreased when it is combined with Apalutamide.Approved, Investigational
AprepitantThe metabolism of Chlorpropamide can be increased when combined with Aprepitant.Approved, Investigational
AripiprazoleThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Aripiprazole.Approved, Investigational
ArmodafinilThe metabolism of Chlorpropamide can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololArotinolol may increase the hypoglycemic activities of Chlorpropamide.Investigational
Arsenic trioxideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
ArticaineThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Articaine.Approved
AsenapineThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Asenapine.Approved
AtazanavirThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the hypoglycemic activities of Chlorpropamide.Approved
AtorvastatinAtorvastatin may increase the hypoglycemic activities of Chlorpropamide.Approved
BalaglitazoneBalaglitazone may increase the hypoglycemic activities of Chlorpropamide.Investigational
BalsalazideBalsalazide may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
BefunololBefunolol may increase the hypoglycemic activities of Chlorpropamide.Experimental
Bempedoic acidBempedoic acid may increase the hypoglycemic activities of Chlorpropamide.Investigational
BendroflumethiazideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypoglycemic activities of Chlorpropamide.Withdrawn
BenzthiazideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Benzthiazide.Approved
BetamethasoneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Betamethasone.Approved, Vet Approved
BetaxololBetaxolol may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
BevantololBevantolol may increase the hypoglycemic activities of Chlorpropamide.Approved
BezafibrateBezafibrate may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
BisoprololBisoprolol may increase the hypoglycemic activities of Chlorpropamide.Approved
BopindololBopindolol may increase the hypoglycemic activities of Chlorpropamide.Approved
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Chlorpropamide.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Chlorpropamide.Approved, Investigational
BrexpiprazoleThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Brexpiprazole.Approved, Investigational
BrofaromineBrofaromine may increase the hypoglycemic activities of Chlorpropamide.Experimental
BucindololBucindolol may increase the hypoglycemic activities of Chlorpropamide.Investigational
BuforminBuformin may increase the hypoglycemic activities of Chlorpropamide.Investigational, Withdrawn
BufuralolBufuralol may increase the hypoglycemic activities of Chlorpropamide.Experimental, Investigational
BumetanideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Bumetanide.Approved
BupranololBupranolol may increase the hypoglycemic activities of Chlorpropamide.Approved
BuserelinThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Buserelin.Approved, Investigational
CanagliflozinCanagliflozin may increase the hypoglycemic activities of Chlorpropamide.Approved
CapecitabineThe metabolism of Chlorpropamide can be decreased when combined with Capecitabine.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may increase the hypoglycemic activities of Chlorpropamide.Experimental, Investigational
CarbocisteineThe risk or severity of adverse effects can be increased when Chlorpropamide is combined with Carbocisteine.Approved, Investigational
CarbutamideCarbutamide may increase the hypoglycemic activities of Chlorpropamide.Experimental
CaroxazoneCaroxazone may increase the hypoglycemic activities of Chlorpropamide.Withdrawn
CarteololCarteolol may increase the hypoglycemic activities of Chlorpropamide.Approved
CarvedilolCarvedilol may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
CastanospermineCastanospermine may increase the hypoglycemic activities of Chlorpropamide.Experimental
CeliprololCeliprolol may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
CeritinibThe serum concentration of Chlorpropamide can be increased when it is combined with Ceritinib.Approved
ChloramphenicolThe metabolism of Chlorpropamide can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Chlorothiazide.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Chlorthalidone.Approved
CholecalciferolThe metabolism of Chlorpropamide can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CiglitazoneCiglitazone may increase the hypoglycemic activities of Chlorpropamide.Experimental
CimetidineThe serum concentration of Chlorpropamide can be increased when it is combined with Cimetidine.Approved, Investigational
CinoxacinCinoxacin may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational, Withdrawn
CiprofibrateCiprofibrate may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
CiprofloxacinThe therapeutic efficacy of Chlorpropamide can be increased when used in combination with Ciprofloxacin.Approved, Investigational
ClofibrateClofibrate may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ClofibrideClofibride may increase the hypoglycemic activities of Chlorpropamide.Experimental
CloranololCloranolol may increase the hypoglycemic activities of Chlorpropamide.Experimental
ClorindioneChlorpropamide may increase the anticoagulant activities of Clorindione.Experimental
ClotrimazoleThe metabolism of Chlorpropamide can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Clozapine.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Chlorpropamide.Approved
CorticotropinThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Corticotropin.Approved, Investigational, Vet Approved
Cortisone acetateThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Cortisone acetate.Approved, Investigational
CrisaboroleThe metabolism of Chlorpropamide can be decreased when combined with Crisaborole.Approved, Investigational
CurcuminThe metabolism of Chlorpropamide can be decreased when combined with Curcumin.Approved, Investigational
CyclobenzaprineCyclobenzaprine may decrease the hypoglycemic activities of Chlorpropamide.Approved
CyclopenthiazideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Cyclopenthiazide.Experimental
Cyproterone acetateThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Chlorpropamide.Approved
DabrafenibThe serum concentration of Chlorpropamide can be decreased when it is combined with Dabrafenib.Approved, Investigational
DanazolThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Danazol.Approved
DapagliflozinDapagliflozin may increase the hypoglycemic activities of Chlorpropamide.Approved
DapoxetineDapoxetine may increase the hypoglycemic activities of Chlorpropamide.Investigational
DarunavirThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Darunavir.Approved
DelavirdineThe metabolism of Chlorpropamide can be decreased when combined with Delavirdine.Approved
DeoxyspergualinDeoxyspergualin may increase the hypoglycemic activities of Chlorpropamide.Investigational
DersalazineDersalazine may increase the hypoglycemic activities of Chlorpropamide.Investigational
DesipramineDesipramine may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
DesogestrelThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Desogestrel.Approved
DesvenlafaxineDesvenlafaxine may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
DexamethasoneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Dexamethasone.Approved, Investigational, Vet Approved
DiazoxideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Diazoxide.Approved
DiclofenacThe protein binding of Chlorpropamide can be decreased when combined with Diclofenac.Approved, Vet Approved
DicoumarolChlorpropamide may increase the anticoagulant activities of Dicoumarol.Approved
DienogestThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Dienogest.Approved
DiflunisalDiflunisal may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
DiphenadioneChlorpropamide may increase the anticoagulant activities of Diphenadione.Experimental
DisopyramideDisopyramide may increase the hypoglycemic activities of Chlorpropamide.Approved
DosulepinThe metabolism of Chlorpropamide can be decreased when combined with Dosulepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Chlorpropamide.Approved, Investigational
DrospirenoneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Drospirenone.Approved
DulaglutideDulaglutide may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
DuloxetineDuloxetine may increase the hypoglycemic activities of Chlorpropamide.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Chlorpropamide.Approved
EfavirenzThe metabolism of Chlorpropamide can be decreased when combined with Efavirenz.Approved, Investigational
EmpagliflozinEmpagliflozin may increase the hypoglycemic activities of Chlorpropamide.Approved
EnglitazoneEnglitazone may increase the hypoglycemic activities of Chlorpropamide.Experimental
EnoxacinEnoxacin may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
EpanololEpanolol may increase the hypoglycemic activities of Chlorpropamide.Experimental
EpinephrineThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Epinephrine.Approved, Vet Approved
EpitizideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Epitizide.Experimental
ErtugliflozinErtugliflozin may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
EsatenololEsatenolol may increase the hypoglycemic activities of Chlorpropamide.Experimental
EscitalopramEscitalopram may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Chlorpropamide can be decreased when combined with Eslicarbazepine acetate.Approved
EsmololEsmolol may increase the hypoglycemic activities of Chlorpropamide.Approved
EsomeprazoleThe metabolism of Chlorpropamide can be decreased when combined with Esomeprazole.Approved, Investigational
EstradiolThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Estradiol.Approved, Investigational, Vet Approved
Estrone sulfateThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Etacrynic acid.Approved, Investigational
EthanolThe risk or severity of adverse effects can be increased when Chlorpropamide is combined with Ethanol.Approved
Ethinyl EstradiolThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Ethinyl Estradiol.Approved
Ethyl biscoumacetateChlorpropamide may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethynodiol diacetateThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Ethynodiol diacetate.Approved
EtofibrateEtofibrate may increase the hypoglycemic activities of Chlorpropamide.Approved
EtonogestrelThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoperidoneEtoperidone may increase the hypoglycemic activities of Chlorpropamide.Withdrawn
EtravirineThe metabolism of Chlorpropamide can be decreased when combined with Etravirine.Approved
EverolimusThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Everolimus.Approved
ExenatideExenatide may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
FenofibrateFenofibrate may increase the hypoglycemic activities of Chlorpropamide.Approved
Fenofibric acidThe risk or severity of hypoglycemia can be increased when Fenofibric acid is combined with Chlorpropamide.Approved
FleroxacinFleroxacin may increase the hypoglycemic activities of Chlorpropamide.Approved
FloxuridineThe metabolism of Chlorpropamide can be decreased when combined with Floxuridine.Approved
FluconazoleThe serum concentration of Chlorpropamide can be increased when it is combined with Fluconazole.Approved, Investigational
FludrocortisoneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Fludrocortisone.Approved, Investigational
FluindioneChlorpropamide may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineFlumequine may increase the hypoglycemic activities of Chlorpropamide.Withdrawn
FluorouracilThe metabolism of Chlorpropamide can be decreased when combined with Fluorouracil.Approved
FluoxetineFluoxetine may increase the hypoglycemic activities of Chlorpropamide.Approved, Vet Approved
FluoxymesteroneFluoxymesterone may increase the hypoglycemic activities of Chlorpropamide.Approved, Illicit
FluvoxamineFluvoxamine may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
FosamprenavirThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Fosamprenavir.Approved
FosphenytoinThe metabolism of Chlorpropamide can be increased when combined with Fosphenytoin.Approved, Investigational
FurazolidoneFurazolidone may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational, Vet Approved
FurosemideThe therapeutic efficacy of Chlorpropamide can be increased when used in combination with Furosemide.Approved, Vet Approved
GarenoxacinGarenoxacin may increase the hypoglycemic activities of Chlorpropamide.Investigational
GatifloxacinGatifloxacin may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
GemfibrozilThe metabolism of Chlorpropamide can be decreased when combined with Gemfibrozil.Approved
GemifloxacinGemifloxacin may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
GlibornurideGlibornuride may increase the hypoglycemic activities of Chlorpropamide.Investigational, Withdrawn
GliclazideChlorpropamide may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideGlimepiride may increase the hypoglycemic activities of Chlorpropamide.Approved
GlipizideChlorpropamide may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GliquidoneGliquidone may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
GLPG-0492GLPG-0492 may increase the hypoglycemic activities of Chlorpropamide.Investigational
GlyburideChlorpropamide may increase the hypoglycemic activities of Glyburide.Approved
GoserelinThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Goserelin.Approved
GrepafloxacinGrepafloxacin may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational, Withdrawn
GuacetisalGuacetisal may increase the hypoglycemic activities of Chlorpropamide.Experimental
GusperimusGusperimus may increase the hypoglycemic activities of Chlorpropamide.Investigational
HarmalineHarmaline may increase the hypoglycemic activities of Chlorpropamide.Experimental
Hemoglobin crosfumarilHemoglobin crosfumaril may increase the hypoglycemic activities of Chlorpropamide.Experimental
HistrelinThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Histrelin.Approved
HydracarbazineHydracarbazine may increase the hypoglycemic activities of Chlorpropamide.Experimental
HydrochlorothiazideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Hydroflumethiazide.Approved, Investigational
Hydroxyprogesterone caproateThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Hydroxyprogesterone caproate.Approved, Investigational
IbuprofenThe protein binding of Chlorpropamide can be decreased when combined with Ibuprofen.Approved
IloperidoneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Iloperidone.Approved
IndalpineIndalpine may increase the hypoglycemic activities of Chlorpropamide.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Indapamide.Approved
IndenololIndenolol may increase the hypoglycemic activities of Chlorpropamide.Withdrawn
IndinavirThe metabolism of Chlorpropamide can be decreased when combined with Indinavir.Approved
Insulin AspartChlorpropamide may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirChlorpropamide may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineInsulin Glargine may increase the hypoglycemic activities of Chlorpropamide.Approved
Insulin GlulisineChlorpropamide may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanInsulin Human may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
Insulin LisproInsulin Lispro may increase the hypoglycemic activities of Chlorpropamide.Approved
Insulin PorkInsulin Pork may increase the hypoglycemic activities of Chlorpropamide.Approved
IproclozideIproclozide may increase the hypoglycemic activities of Chlorpropamide.Withdrawn
IproniazidIproniazid may increase the hypoglycemic activities of Chlorpropamide.Withdrawn
IrbesartanThe metabolism of Chlorpropamide can be decreased when combined with Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypoglycemic activities of Chlorpropamide.Approved
IsoniazidThe metabolism of Chlorpropamide can be decreased when combined with Isoniazid.Approved, Investigational
KetoconazoleThe metabolism of Chlorpropamide can be decreased when combined with Ketoconazole.Approved, Investigational
KetorolacThe protein binding of Chlorpropamide can be decreased when combined with Ketorolac.Approved
LabetalolLabetalol may increase the hypoglycemic activities of Chlorpropamide.Approved
LandiololLandiolol may increase the hypoglycemic activities of Chlorpropamide.Investigational
LanreotideChlorpropamide may increase the hypoglycemic activities of Lanreotide.Approved
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Chlorpropamide.Approved
LeflunomideThe metabolism of Chlorpropamide can be decreased when combined with Leflunomide.Approved, Investigational
LeuprolideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Leuprolide.Approved, Investigational
LevobetaxololLevobetaxolol may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
LevobunololLevobunolol may increase the hypoglycemic activities of Chlorpropamide.Approved
LevofloxacinLevofloxacin may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
LevonorgestrelThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LinagliptinLinagliptin may increase the hypoglycemic activities of Chlorpropamide.Approved
Lipoic AcidLipoic Acid may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational, Nutraceutical
LiraglutideLiraglutide may increase the hypoglycemic activities of Chlorpropamide.Approved
LixisenatideLixisenatide may increase the hypoglycemic activities of Chlorpropamide.Approved
LobeglitazoneLobeglitazone may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
LomefloxacinLomefloxacin may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
LopinavirThe metabolism of Chlorpropamide can be increased when combined with Lopinavir.Approved
LovastatinThe metabolism of Chlorpropamide can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Chlorpropamide can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Chlorpropamide can be decreased when it is combined with Lumacaftor.Approved
LurasidoneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Lurasidone.Approved, Investigational
MebanazineMebanazine may increase the hypoglycemic activities of Chlorpropamide.Withdrawn
MecaserminChlorpropamide may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MedrogestoneThe serum concentration of Chlorpropamide can be decreased when it is combined with Medrogestone.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Megestrol acetateThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Megestrol acetate.Approved, Investigational, Vet Approved
MepindololMepindolol may increase the hypoglycemic activities of Chlorpropamide.Experimental
MesalazineMesalazine may increase the hypoglycemic activities of Chlorpropamide.Approved
MesteroloneMesterolone may increase the hypoglycemic activities of Chlorpropamide.Experimental
MestranolThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Mestranol.Approved
MetforminMetformin may increase the hypoglycemic activities of Chlorpropamide.Approved
MethenamineThe serum concentration of Chlorpropamide can be increased when it is combined with Methenamine.Approved, Vet Approved
MethotrimeprazineThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
MethyclothiazideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Methyclothiazide.Approved
Methyl salicylateMethyl salicylate may increase the hypoglycemic activities of Chlorpropamide.Approved, Vet Approved
Methylene blueMethylene blue may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
MethylprednisoloneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Methylprednisolone.Approved, Vet Approved
MethyltestosteroneMethyltestosterone may increase the hypoglycemic activities of Chlorpropamide.Approved
MetipranololMetipranolol may increase the hypoglycemic activities of Chlorpropamide.Approved
MetolazoneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Metolazone.Approved
MetoprololMetoprolol may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
MetreleptinMetreleptin may increase the hypoglycemic activities of Chlorpropamide.Approved
MiconazoleMiconazole may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational, Vet Approved
MidostaurinThe metabolism of Chlorpropamide can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneThe serum concentration of Chlorpropamide can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolMiglitol may increase the hypoglycemic activities of Chlorpropamide.Approved
MiglustatMiglustat may increase the hypoglycemic activities of Chlorpropamide.Approved
MilnacipranMilnacipran may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
MinaprineMinaprine may increase the hypoglycemic activities of Chlorpropamide.Approved
MitiglinideMitiglinide may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ModafinilThe metabolism of Chlorpropamide can be decreased when combined with Modafinil.Approved, Investigational
MoxifloxacinThe therapeutic efficacy of Chlorpropamide can be increased when used in combination with Moxifloxacin.Approved, Investigational
NabiloneThe metabolism of Chlorpropamide can be decreased when combined with Nabilone.Approved, Investigational
NadololNadolol may increase the hypoglycemic activities of Chlorpropamide.Approved
Nalidixic AcidNalidixic Acid may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Chlorpropamide.Approved
NandroloneNandrolone may increase the hypoglycemic activities of Chlorpropamide.Experimental, Investigational
Nandrolone decanoateNandrolone decanoate may increase the hypoglycemic activities of Chlorpropamide.Approved, Illicit
NaproxenThe protein binding of Chlorpropamide can be decreased when combined with Naproxen.Approved, Vet Approved
NateglinideChlorpropamide may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololNebivolol may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
NefazodoneNefazodone may increase the hypoglycemic activities of Chlorpropamide.Approved, Withdrawn
NemonoxacinNemonoxacin may increase the hypoglycemic activities of Chlorpropamide.Investigational
NetoglitazoneNetoglitazone may increase the hypoglycemic activities of Chlorpropamide.Experimental
NiacinThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Niacin.Approved, Investigational, Nutraceutical
NialamideNialamide may increase the hypoglycemic activities of Chlorpropamide.Withdrawn
NicardipineThe metabolism of Chlorpropamide can be decreased when combined with Nicardipine.Approved, Investigational
NilotinibThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Nilotinib.Approved, Investigational
NimesulideThe protein binding of Chlorpropamide can be decreased when combined with Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinNitroaspirin may increase the hypoglycemic activities of Chlorpropamide.Investigational
NorethisteroneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Norethisterone.Approved
NorfloxacinNorfloxacin may increase the hypoglycemic activities of Chlorpropamide.Approved
NorgestimateThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Norgestimate.Approved, Investigational
OctamoxinOctamoxin may increase the hypoglycemic activities of Chlorpropamide.Withdrawn
OctreotideOctreotide may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
OfloxacinOfloxacin may increase the hypoglycemic activities of Chlorpropamide.Approved
OlanzapineThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Olanzapine.Approved, Investigational
OlsalazineOlsalazine may increase the hypoglycemic activities of Chlorpropamide.Approved
OxandroloneOxandrolone may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
Oxolinic acidOxolinic acid may increase the hypoglycemic activities of Chlorpropamide.Experimental
OxprenololOxprenolol may increase the hypoglycemic activities of Chlorpropamide.Approved
OxymetholoneOxymetholone may increase the hypoglycemic activities of Chlorpropamide.Approved, Illicit
PaliperidoneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Paliperidone.Approved
PantoprazoleThe metabolism of Chlorpropamide can be decreased when combined with Pantoprazole.Approved
PargylinePargyline may increase the hypoglycemic activities of Chlorpropamide.Approved
ParoxetineParoxetine may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
PasireotideChlorpropamide may increase the hypoglycemic activities of Pasireotide.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Chlorpropamide.Approved
PazufloxacinPazufloxacin may increase the hypoglycemic activities of Chlorpropamide.Investigational
PefloxacinPefloxacin may increase the hypoglycemic activities of Chlorpropamide.Approved
PegvisomantPegvisomant may increase the hypoglycemic activities of Chlorpropamide.Approved
PenbutololPenbutolol may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
PentamidineChlorpropamide may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
PhenelzinePhenelzine may increase the hypoglycemic activities of Chlorpropamide.Approved
PhenforminPhenformin may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational, Withdrawn
PhenindioneChlorpropamide may increase the anticoagulant activities of Phenindione.Approved, Investigational
PheniprazinePheniprazine may increase the hypoglycemic activities of Chlorpropamide.Withdrawn
PhenobarbitalThe metabolism of Chlorpropamide can be increased when combined with Phenobarbital.Approved, Investigational
PhenoxypropazinePhenoxypropazine may increase the hypoglycemic activities of Chlorpropamide.Withdrawn
PhenprocoumonChlorpropamide may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
Phenyl aminosalicylatePhenyl aminosalicylate may increase the hypoglycemic activities of Chlorpropamide.Approved
PhenytoinThe metabolism of Chlorpropamide can be increased when combined with Phenytoin.Approved, Vet Approved
PindololPindolol may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
PioglitazonePioglitazone may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
Pipemidic acidPipemidic acid may increase the hypoglycemic activities of Chlorpropamide.Experimental
PiperazineThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Piperazine.Approved, Vet Approved
PipotiazineThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Pipotiazine.Approved, Investigational
PirlindolePirlindole may increase the hypoglycemic activities of Chlorpropamide.Approved
Piromidic acidPiromidic acid may increase the hypoglycemic activities of Chlorpropamide.Experimental
PivhydrazinePivhydrazine may increase the hypoglycemic activities of Chlorpropamide.Withdrawn
Platelet Activating FactorPlatelet Activating Factor may increase the hypoglycemic activities of Chlorpropamide.Experimental
PolythiazideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Polythiazide.Approved
PractololPractolol may increase the hypoglycemic activities of Chlorpropamide.Approved
PramlintidePramlintide may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
PrednisoloneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Prednisolone.Approved, Vet Approved
PrednisoneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Prednisone.Approved, Vet Approved
PregabalinThe risk or severity of heart failure can be increased when Pregabalin is combined with Chlorpropamide.Approved, Illicit, Investigational
PrimidoneThe metabolism of Chlorpropamide can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe protein binding of Chlorpropamide can be decreased when combined with Probenecid.Approved, Investigational
ProcaineProcaine may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ProgesteroneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Progesterone.Approved, Vet Approved
PropafenonePropafenone may increase the hypoglycemic activities of Chlorpropamide.Approved
PropranololPropranolol may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Chlorpropamide.Approved
PrulifloxacinPrulifloxacin may increase the hypoglycemic activities of Chlorpropamide.Investigational
PyrimethamineThe metabolism of Chlorpropamide can be decreased when combined with Pyrimethamine.Approved, Investigational, Vet Approved
QuetiapineThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Quetiapine.Approved
QuinethazoneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Quinethazone.Approved
QuinineThe metabolism of Chlorpropamide can be decreased when combined with Quinine.Approved
RanitidineThe serum concentration of Chlorpropamide can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Chlorpropamide.Approved, Investigational
RasagilineRasagiline may increase the hypoglycemic activities of Chlorpropamide.Approved
RepaglinideChlorpropamide may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RifampicinThe serum concentration of Chlorpropamide can be decreased when it is combined with Rifampicin.Approved
RifapentineThe metabolism of Chlorpropamide can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Chlorpropamide.Approved, Investigational
RisperidoneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Risperidone.Approved, Investigational
RitonavirThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Ritonavir.Approved, Investigational
RivoglitazoneRivoglitazone may increase the hypoglycemic activities of Chlorpropamide.Experimental, Investigational
RonifibrateRonifibrate may increase the hypoglycemic activities of Chlorpropamide.Experimental
RosiglitazoneThe therapeutic efficacy of Chlorpropamide can be increased when used in combination with Rosiglitazone.Approved, Investigational
RosoxacinRosoxacin may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
RosuvastatinThe therapeutic efficacy of Chlorpropamide can be increased when used in combination with Rosuvastatin.Approved
RucaparibThe metabolism of Chlorpropamide can be decreased when combined with Rucaparib.Approved, Investigational
SafrazineSafrazine may increase the hypoglycemic activities of Chlorpropamide.Withdrawn
Salicylic acidSalicylic acid may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational, Vet Approved
SaquinavirThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Saquinavir.Approved, Investigational
SaxagliptinSaxagliptin may increase the hypoglycemic activities of Chlorpropamide.Approved
SecobarbitalThe metabolism of Chlorpropamide can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational, Vet Approved
SemaglutideSemaglutide may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
SertralineThe metabolism of Chlorpropamide can be decreased when combined with Sertraline.Approved
SildenafilThe metabolism of Chlorpropamide can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Chlorpropamide.Approved
Silver sulfadiazineThe therapeutic efficacy of Chlorpropamide can be increased when used in combination with Silver sulfadiazine.Approved, Vet Approved
SimfibrateSimfibrate may increase the hypoglycemic activities of Chlorpropamide.Experimental
SirolimusThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Sirolimus.Approved, Investigational
SitafloxacinSitafloxacin may increase the hypoglycemic activities of Chlorpropamide.Experimental, Investigational
SitagliptinSitagliptin may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
SorafenibThe metabolism of Chlorpropamide can be decreased when combined with Sorafenib.Approved, Investigational
SotagliflozinSotagliflozin may increase the hypoglycemic activities of Chlorpropamide.Investigational
SotalolSotalol may increase the hypoglycemic activities of Chlorpropamide.Approved
SparfloxacinSparfloxacin may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
StanoloneStanolone may increase the hypoglycemic activities of Chlorpropamide.Illicit, Investigational
StanozololStanozolol may increase the hypoglycemic activities of Chlorpropamide.Approved, Vet Approved
StiripentolThe metabolism of Chlorpropamide can be decreased when combined with Stiripentol.Approved
SulfadiazineThe metabolism of Chlorpropamide can be decreased when combined with Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleThe metabolism of Chlorpropamide can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineSulfasalazine may increase the hypoglycemic activities of Chlorpropamide.Approved
SulfisoxazoleThe metabolism of Chlorpropamide can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe protein binding of Chlorpropamide can be decreased when combined with Sulindac.Approved, Investigational
SulodexideSulodexide may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
SumatriptanThe therapeutic efficacy of Chlorpropamide can be increased when used in combination with Sumatriptan.Approved, Investigational
SunitinibChlorpropamide may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TacrolimusThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Tacrolimus.Approved, Investigational
TalinololTalinolol may increase the hypoglycemic activities of Chlorpropamide.Investigational
TaspoglutideTaspoglutide may increase the hypoglycemic activities of Chlorpropamide.Investigational
TemafloxacinTemafloxacin may increase the hypoglycemic activities of Chlorpropamide.Withdrawn
TemsirolimusThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Temsirolimus.Approved
TerbutalineTerbutaline may increase the hypoglycemic activities of Chlorpropamide.Approved
TertatololTertatolol may increase the hypoglycemic activities of Chlorpropamide.Experimental
TestosteroneTestosterone may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
Testosterone cypionateTestosterone cypionate may increase the hypoglycemic activities of Chlorpropamide.Approved
Testosterone enanthateTestosterone enanthate may increase the hypoglycemic activities of Chlorpropamide.Approved
Testosterone propionateTestosterone propionate may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateTestosterone undecanoate may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
TicagrelorThe metabolism of Chlorpropamide can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Chlorpropamide can be decreased when combined with Ticlopidine.Approved
TimololTimolol may increase the hypoglycemic activities of Chlorpropamide.Approved
TioclomarolChlorpropamide may increase the anticoagulant activities of Tioclomarol.Experimental
TipranavirThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Tipranavir.Approved, Investigational
TolazamideChlorpropamide may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolbutamideThe metabolism of Chlorpropamide can be decreased when combined with Tolbutamide.Approved, Investigational
Tolfenamic AcidThe protein binding of Chlorpropamide can be decreased when combined with Tolfenamic Acid.Approved, Investigational
ToloxatoneToloxatone may increase the hypoglycemic activities of Chlorpropamide.Approved
TopiroxostatThe metabolism of Chlorpropamide can be decreased when combined with Topiroxostat.Approved, Investigational
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Chlorpropamide.Approved, Investigational
TorasemideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Torasemide.Approved
TranylcypromineThe metabolism of Chlorpropamide can be decreased when combined with Tranylcypromine.Approved, Investigational
TriamcinoloneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Triamcinolone.Approved, Vet Approved
TrichlormethiazideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Trichlormethiazide.Approved, Vet Approved
TrimethoprimThe metabolism of Chlorpropamide can be decreased when combined with Trimethoprim.Approved, Vet Approved
TriptorelinThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Triptorelin.Approved, Vet Approved
TroglitazoneTroglitazone may increase the hypoglycemic activities of Chlorpropamide.Investigational, Withdrawn
Trolamine salicylateTrolamine salicylate may increase the hypoglycemic activities of Chlorpropamide.Approved
TrovafloxacinTrovafloxacin may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational, Withdrawn
UbidecarenoneThe therapeutic efficacy of Chlorpropamide can be increased when used in combination with Ubidecarenone.Approved, Investigational, Nutraceutical
ValsartanThe metabolism of Chlorpropamide can be decreased when combined with Valsartan.Approved, Investigational
VenlafaxineVenlafaxine may increase the hypoglycemic activities of Chlorpropamide.Approved
VildagliptinVildagliptin may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
VincristineThe excretion of Vincristine can be decreased when combined with Chlorpropamide.Approved, Investigational
VogliboseVoglibose may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
VoriconazoleThe serum concentration of Chlorpropamide can be increased when it is combined with Voriconazole.Approved, Investigational
VorinostatThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Vorinostat.Approved, Investigational
WarfarinChlorpropamide may increase the anticoagulant activities of Warfarin.Approved
ZafirlukastThe metabolism of Chlorpropamide can be decreased when combined with Zafirlukast.Approved, Investigational
ZimelidineZimelidine may increase the hypoglycemic activities of Chlorpropamide.Withdrawn
ZiprasidoneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Ziprasidone.Approved
ZucapsaicinThe metabolism of Chlorpropamide can be decreased when combined with Zucapsaicin.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Food reduces the rate of absorption.
  • Take 30 minutes before meal.

References

Synthesis Reference

McLamore, W.M.; U S . Patent 3,349,124; October 24,1967; assigned to Chas. Pfizer Co., Inc.

General References
Not Available
External Links
Human Metabolome Database
HMDB0014810
KEGG Drug
D00271
PubChem Compound
2727
PubChem Substance
46506402
ChemSpider
2626
BindingDB
50344965
ChEBI
3650
ChEMBL
CHEMBL498
Therapeutic Targets Database
DAP000923
PharmGKB
PA448966
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Chlorpropamide
ATC Codes
A10BB02 — Chlorpropamide
AHFS Codes
  • 68:20.20 — Sulfonylureas
MSDS
Download (35.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentImpaired Glucose Tolerance (IGT) / Type 2 Diabetes Mellitus1
Not AvailableCompletedNot AvailableType 2 Diabetes Mellitus3
Not AvailableCompletedScreeningDiabetes Insipidus / Diabetes Insipidus, Neurohypophyseal1

Pharmacoeconomics

Manufacturers
  • Barr laboratories inc
  • Clonmel healthcare ltd
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Halsey drug co inc
  • Ivax pharmaceuticals inc
  • Mylan pharmaceuticals inc
  • Par pharmaceutical inc
  • Pliva inc
  • Sandoz inc
  • Superpharm corp
  • Teva pharmaceuticals usa inc
  • Usl pharma inc
  • Watson laboratories inc
  • Pfizer laboratories div pfizer inc
Packagers
  • Central Texas Community Health Centers
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • H and H Laboratories
  • Major Pharmaceuticals
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Nucare Pharmaceuticals Inc.
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Pfizer Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Pliva Inc.
  • Prepackage Specialists
  • Prescript Pharmaceuticals
  • Qualitest
  • UDL Laboratories
  • Wyeth Pharmaceuticals
Dosage forms
FormRouteStrength
TabletOral100 mg
TabletOral250 mg
TabletOral100 mg/1
TabletOral250 mg/1
Prices
Unit descriptionCostUnit
Diabinese 250 mg tablet1.34USD tablet
Diabinese 100 mg tablet0.61USD tablet
Chlorpropamide 250 mg tablet0.46USD tablet
Chlorpropamide 100 mg tablet0.33USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)129.2-129.8McLamore, W.M.; U S . Patent 3,349,124; October 24,1967; assigned to Chas. Pfizer Co., Inc.
water solubility258 mg/L (at 37 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.27HANSCH,C ET AL. (1995)
logS-3.03ADME Research, USCD
pKa5.13LIPINSKI,CA ET AL. (1991)
Predicted Properties
PropertyValueSource
Water Solubility0.157 mg/mLALOGPS
logP2.15ALOGPS
logP1.94ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)4.33ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area75.27 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity65.43 m3·mol-1ChemAxon
Polarizability27.06 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9969
Blood Brain Barrier+0.8087
Caco-2 permeable-0.6198
P-glycoprotein substrateNon-substrate0.6087
P-glycoprotein inhibitor INon-inhibitor0.9009
P-glycoprotein inhibitor IINon-inhibitor0.9533
Renal organic cation transporterNon-inhibitor0.8747
CYP450 2C9 substrateSubstrate0.5553
CYP450 2D6 substrateNon-substrate0.8806
CYP450 3A4 substrateNon-substrate0.7042
CYP450 1A2 substrateNon-inhibitor0.9044
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.9592
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6454
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.7685
BiodegradationNot ready biodegradable0.9206
Rat acute toxicity2.1413 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9072
hERG inhibition (predictor II)Non-inhibitor0.9306
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0002-0093000000-fa4d8bff1a5b0d68d8ea
MS/MS Spectrum - , positiveLC-MS/MSsplash10-006x-0910000000-a09d8795a568a12a0da3
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03dr-2910000000-7ee6a1f4754e3058ddb6

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzenesulfonamides
Direct Parent
Benzenesulfonamides
Alternative Parents
Benzenesulfonyl compounds / Sulfonylureas / Chlorobenzenes / Aryl chlorides / Organosulfonic acids and derivatives / Aminosulfonyl compounds / Propargyl-type 1,3-dipolar organic compounds / Carboximidic acids and derivatives / Organopnictogen compounds / Organooxygen compounds
show 3 more
Substituents
Benzenesulfonamide / Benzenesulfonyl group / Chlorobenzene / Halobenzene / Sulfonylurea / Aryl chloride / Aryl halide / Organic sulfonic acid or derivatives / Organosulfonic acid or derivatives / Sulfonyl
show 15 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
monochlorobenzenes, N-sulfonylurea (CHEBI:3650)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Sulfonylurea receptor activity
Specific Function
Subunit of the beta-cell ATP-sensitive potassium channel (KATP). Regulator of ATP-sensitive K(+) channels and insulin release.
Gene Name
ABCC8
Uniprot ID
Q09428
Uniprot Name
ATP-binding cassette sub-family C member 8
Molecular Weight
176990.36 Da
References
  1. Mizuno CS, Chittiboyina AG, Kurtz TW, Pershadsingh HA, Avery MA: Type 2 diabetes and oral antihyperglycemic drugs. Curr Med Chem. 2008;15(1):61-74. [PubMed:18220763]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name
SLC15A1
Uniprot ID
P46059
Uniprot Name
Solute carrier family 15 member 1
Molecular Weight
78805.265 Da
References
  1. Terada T, Sawada K, Saito H, Hashimoto Y, Inui K: Inhibitory effect of novel oral hypoglycemic agent nateglinide (AY4166) on peptide transporters PEPT1 and PEPT2. Eur J Pharmacol. 2000 Mar 24;392(1-2):11-7. [PubMed:10748266]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Peptide:proton symporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name
SLC15A2
Uniprot ID
Q16348
Uniprot Name
Solute carrier family 15 member 2
Molecular Weight
81782.77 Da
References
  1. Terada T, Sawada K, Saito H, Hashimoto Y, Inui K: Inhibitory effect of novel oral hypoglycemic agent nateglinide (AY4166) on peptide transporters PEPT1 and PEPT2. Eur J Pharmacol. 2000 Mar 24;392(1-2):11-7. [PubMed:10748266]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Uwai Y, Saito H, Hashimoto Y, Inui K: Inhibitory effect of anti-diabetic agents on rat organic anion transporter rOAT1. Eur J Pharmacol. 2000 Jun 16;398(2):193-7. [PubMed:10854830]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:43